



UNIVERSITY OF LEEDS

This is a repository copy of *Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/158608/>

Version: Accepted Version

Article:

D'Ambrosio, L, Touati, N, Blay, J et al. (25 more authors) (2020) Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer*. cncr.32795. ISSN 0008-543X

<https://doi.org/10.1002/cncr.32795>

© 2020 American Cancer Society. This is an author produced version of a paper published in *Cancer*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Running title: First-line treatments for leiomyosarcoma

Authors

Lorenzo D'Ambrosio MD, PhD^{a,d}; Nathan Touati PhD^b; Jean-Yves Blay MD, Prof^c; Giovanni Grignani MD^d; Ronan Flippot MD^e; Anna M Czarnecka MD^f; Sophie Piperno-Neumann MD^g; Javier Martin-Broto MD^h; Roberta Sanfilippo MDⁱ; Daniela Katz MD^{j,1}; Florence Duffaud MD^k; Bruno Vincenzi MD^l; Daniel P. Stark MD^m; Filomena Mazzeo MDⁿ; Armin Tuchscherer MD^o; Christine Chevreau MD^p; Jenny Sherriff MD^q; Anna Estival MD^r; Saskia Litière PhD^b; Ward Sents PhD^b; Isabelle Ray-Coquard MD PhD^c; Francesco Tolomeo MD^d; Axel Le Cesne MD^e; Piotr Rutkowski MD^f; Silvia Stacchiotti MDⁱ; Bernd Kasper MD^s; Hans Gelderblom MD^t; Alessandro Gronchi MD^u on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Affiliations

^aUniversity of Torino, Department of Oncology, Torino, Italy;

^bEuropean Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium;

^cCentre Leon Berard & University Claude Bernard Lyon I, EURACAN, LYRICAN, Lyon, France;

^dSarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy.

^eDepartment of Medicine, Gustave Roussy, Villejuif Cedex, France;

^fDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Gliwice, Poland & Department of Experimental Pharmacology, Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland;

^gMedical Oncology Department, Institut Curie, Paris, France;

^hVirgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/CSIC/Universidad de Sevilla, Sevilla, Spain;

ⁱMedical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;

^jOncology Department, Sharett Institute of Oncology, Hadassah-Hebrew University Jerusalem, Israel. ¹Present address: Oncology Institute, Assaf Harofeh Medical Center, Zrifin, Israel;

^kService d'Oncologie Médicale CHU la Timone, Aix- Marseille Université Marseille, Marseille, France;

^lDepartment of Medical Oncology, University Campus Bio-Medico of Rome, Rome, Italy;

^mSt James's Institute of Oncology, Leeds Institute of Cancer and Pathology, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom;

ⁿMedical Oncology, Clinique Universitaire Saint-Luc, Woluwe-Saint-Lambert, Belgium;

^oDepartment I of Internal Medicine, University Hospital Cologne, Köln, Germany;

^pInstitut Universitaire du Cancer de Toulouse (IUCT) Oncopole - Institut Claudius Regaud; Toulouse, France;

^qCancer Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom;

^rInstituto Catalán de Oncología (ICO) Badalona, Barcelona, Spain;

^sUniversity of Heidelberg, Mannheim University Medical Center, Interdisciplinary Tumor Center, Sarcoma Unit, Mannheim, Germany;

^tDepartment of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands;

^uDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Corresponding author

Lorenzo D'Ambrosio, MD PhD.

University of Torino, Department of Oncology, Torino, Italy;

Candiolo Cancer Institute – FPO, IRCCS

Strada Provinciale 142, Km 3.95 – 10060 Candiolo (Torino), Italy

email: lorenzo.dambrosio.md@gmail.it

Telephone: +39 011 99 33 628

Fax: +39 011 99 33 290

FUNDING

No external funding supported this study. Nathan Touati received a fellowship from the EORTC Cancer Research Fund through a grant from the EORTC Soft Tissue and Bone Sarcoma Group.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Lorenzo D'Ambrosio:Travel/Accommodations/Expenses:PharmaMar,Lilly.

Jean-Yves Blay:Honoraria:Bayer;GlaxoSmithKline;Lilly;Novartis;PharmaMar;Roche.

Consulting/Advisory Role:Bayer;GlaxoSmithKline;Merck;Novartis;PharmaMar;Roche.

Research Funding:Bayer(Inst);GSK(Inst);Novartis(Inst);PharmaMar(Inst);Roche(Inst).

Other Relationship:Innate Pharma.

Giovanni Grignani:Honoraria:Bayer;Eisai;Lilly;Novartis;Pfizer;PharmaMar.

Consulting/Advisory Role:Bayer;Eisai;Lilly;Novartis;Pfizer;PharmaMar.

Research Funding:Bayer;Novartis;PharmaMar.

Travel/Accommodations/Expenses:PharmaMar.

Ronan Flippot:Travel/Accommodations/Expenses: Pfizer;Novartis

Anna Malgorzata Czarnecka:Speakers' Bureau:Bristol-Myers-Squibb;MSD;Roche.

Travel/Accommodations/Expenses:Bristol-Myers-Squibb;Lilly;MSD;Novartis;Pfizer;Roche.

Javier Martin Broto:Honoraria:Lilly;PharmaMar.

Consulting/Advisory Role:PharmaMar;GlaxoSmithKline;Novartis;Amgen;Bayer.

Speakers' Bureau:PharmaMar.

Research Funding:PharmaMar,GlaxoSmithKline;Novartis(Inst);Eisai(Inst);Lilly(Inst).

Expert Testimony:PharmaMar;Novartis.

Travel/Accommodations/Expenses:PharmaMar;Pfizer.

Daniela Katz:Honoraria:Lilly; Roche.

Consulting/Advisory Role:Novartis.

Research Funding:Bristol-Myers-Squibb;Novartis.

Florence Duffaud:Honoraria:Bayer;PharmaMar.

Consulting/Advisory Role:Bayer;Lilly;Novartis;PharmaMar.

Travel/Accommodations/Expenses:PharmaMar.

Daniel P. Stark:Research Funding:PharmaMar.

Filomena Mazzeo:Honoraria:Novartis;PharmaMar;Lilly;Eisai;Pfizer.

Consulting/Advisory Role:Lilly.

Travel/Accommodations/Expenses:PharmaMar.

Christine Chevreau: Consulting/Advisory Role:Bristol-Myers-Squibb;Novartis;Pfizer.

Travel/Accommodations/Expenses:Ipsen.

Isabelle Ray-Coquard: Honoraria:AstraZeneca;PharmaMar;Roche.

Consulting/Advisory Role:Abbvie;Amgen;Pfizer.

Axel Le Cesne: Honoraria:Novartis;Lilly;PharmaMar;Amgen;Pfizer;Eisai.

Piotr Rutkowski: Honoraria:Amgen;Bristol-Myers-Squibb;MSD;Novartis;Pfizer;Roche.

Consulting/Advisory Role:Blueprint Medicines;MSD;Novartis.

Speakers' Bureau:Bristol-Myers-Squibb;Novartis;Pfizer.

Research Funding:BMS Brazil(Inst);Novartis(Inst).

Travel/Accommodations/Expenses:Orphan Europe.

Silvia Stacchiotti: Honoraria:Lilly;PharmaMar;Takeda.

Consulting/Advisory Role:Bayer;Epizyme;Immune Design;Lilly;MaxiVax;PharmaMar.

Research Funding:Advenchen Laboratories(Inst);Amgen(Inst);Bayer(Inst);Daiichi-

Sankyo(Inst);Epizyme(Inst);Lilly(Inst);Novartis(Inst);Pfizer(Inst);PharmaMar(Inst).

Travel/Accommodations/Expenses:PharmaMar.

Bernd Kasper:Honoraria:Bayer;Lilly;Novartis;PharmaMar.

Consulting/Advisory Role:Bayer;Eisai;Lilly.

Research Funding:PharmaMar.

Alessandro Gronchi:Honoraria:Lilly;Novartis;Pfizer;PharmaMar.

Consulting/Advisory Role:Bayer;Lilly;Nanobiotix;Novartis;Pfizer;PharmaMar.

Research Funding:PharmaMar(Inst).

Travel/Accommodations/Expenses:Nanobiotix;PharmaMar.

All other authors declare no potential conflicts of interest.

AUTHOR CONTRIBUTIONS STATEMENT

Lorenzo D'Ambrosio: conceptualization, data curation, methodology, resources, supervision, validation, visualization, writing - original draft, review and editing. Nathan Touati: data curation, formal analysis, methodology, validation, visualization, writing review and editing

Jean-Yves Blay: data curation, resources, writing review and editing. Giovanni Grignani; data curation, resources, writing review and editing Ronan Flippot. Anna M Czarnecka: data curation, resources, writing review and editing. Sophie Piperno-Neumann: data curation, resources, writing review and editing. Javier Martin-Broto: data curation, resources, writing review and editing.

Roberta Sanfilippo: data curation, resources, writing review and editing. Daniela Katz: data curation, resources, writing review and editing. Florence Duffaud: data curation, resources, writing review and editing. Bruno Vincenzi: data curation, resources, writing review and editing.

Daniel P. Stark: data curation, resources, writing review and editing. Filomena Mazzeo: data curation, resources, writing review and editing. Armin Tuchscherer: data curation, resources, writing review and editing. Christine Chevreau: data curation, resources, writing review and editing. Jenny Sherriff: data curation, resources, writing review and editing. Anna Estival: data curation, resources, writing review and editing. Saskia Litière: data curation, formal analysis, methodology, project administration, resources, supervision, validation, writing original draft,

review and editing. Ward Sents: data curation, project administration, resources, writing review and editing. Isabelle Ray-Coquard: data curation, resources, writing review and editing. Francesco Tolomeo: data curation, resources, writing review and editing. Axel Le Cesne: data curation, resources, writing review and editing. Piotr Rutkowski: data curation, resources, writing review and editing. Silvia Stacchiotti: data curation, supervision, validation, visualization, writing original draft, review and editing.

Bernd Kasper: data curation, supervision, validation, visualization, writing original draft, review and editing. Hans Gelderblom: data curation, supervision, validation, visualization, writing original draft, review and editing. Alessandro Gronchi: conceptualization, methodology, supervision, validation, visualization, writing original draft review and editing.

ACKNOWLEDGEMENTS

Nathan Touati received a fellowship from the EORTC Cancer Research Fund through a grant from the EORTC Soft Tissue and Bone Sarcoma Group. Lorenzo D'Ambrosio research activity was partially supported by FRPC 5xmille 2014, Giovanni Grignani research activity was partially supported by FPRC 5xmille 2015. We thank all data managers and study coordinators from the participating centers for their great help.

COUNT

- Text pages: 25
- Abstract word count: 249
- Main text word count: 2771
- Tables: 2 (uploaded as separate files)
- Figures: 3 (including CONSORT diagram)
- Supplementary appendix: 1

PRECIS FOR USE IN THE TABLE OF CONTENTS

- In this propensity score-adjusted multi-Institutional series, doxorubicin+dacarbazine showed the better outcomes for the first-line treatment of advanced leiomyosarcoma warranting further studies
- This series represent a benchmark for the future development of trials in leiomyosarcoma

ABSTRACT

Background: Optimal treatment for advanced leiomyosarcoma is still debated. In the lack of histotype-specific prospective controlled data, we retrospectively evaluated doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone as first-line treatment for advanced/metastatic leiomyosarcoma treated within EORTC-STBSG sites.

Methods: Inclusion criteria: confirmed histological diagnosis, treatment between 1/2010 and 12/2015, measurable disease (RECIST1.1), ECOG performance status ≤ 2 , age ≥ 18 years. Endpoints: progression-free survival (PFS), overall survival (OS), overall response rate (ORR). PFS was analyzed using methods for interval-censored data. Patients were matched according to their propensity scores estimated using a logistic regression model accounting for histology, grade, age, gender, performance status, tumor site and extent.

Results: 303 patients from 18 EORTC-STBSG sites were identified. 117(39%) received doxorubicin+dacarbazine, 71(23%) doxorubicin+ifosfamide, and 115(38%) doxorubicin. In the 2:1:2 propensity score-matched population (205 patients), estimated median PFS was 9.2 (5.2-97), 8.2 (5.2-10.1), and 4.8 months (2.3-6.0), with an ORR of 30.9%, 19.5%, and 25.6% for doxorubicin+dacarbazine, doxorubicin+ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer for doxorubicin+dacarbazine vs. doxorubicin [HR 0.72(0.52-0.99)]. Doxorubicin+dacarbazine reported longer OS [median 36.8 months(27.9-47.2)] compared to both doxorubicin+ifosfamide [21.9 (16.7-33.4), HR 0.65(0.40-1.06)] and doxorubicin [30.3 (21.0-36.3), HR 0.66(0.43-0.99)]. Adjusted analyses retained effect for PFS but not for OS. None of the factors selected for multivariate analysis had significant interaction with the received treatment for both PFS and OS.

Conclusions: This is the largest retrospective study on first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population doxorubicin+dacarbazine showed favorable activity in terms of both ORR and PFS warranting further evaluation in prospective trials.

KEYWORDS

leiomyosarcoma; sarcoma; doxorubicin; dacarbazine; ifosfamide; propensity score; retrospective study.

INTRODUCTION

Soft tissue sarcomas (STS) are a heterogeneous group of tumors encompassing more than 50 different entities. Leiomyosarcoma is one of the most common histotypes representing about 10-20% of all STS.^{1,2} This tumor may arise in any site of the body, being retroperitoneum, limbs/girdles, and uterus more frequently affected.^{1,2} Despite the absence of distinctive morphologic features, there is some genetic and clinical evidence supporting that site of origin may affect both sensitivity to treatments and prognosis.¹⁻⁷

Overall, leiomyosarcoma management is multidisciplinary, but surgery still represents the cornerstone of treatment in localized disease. Unfortunately, despite optimal locoregional treatments, leiomyosarcoma may relapse.^{1,2,8-10} For patients with metastatic disease, first-line chemotherapy is currently based on anthracyclines, including doxorubicin alone or in combination with ifosfamide or dacarbazine.¹¹⁻¹³

Whatever treatment is used, complete remission is a rare event and second- and further-line therapies obtain poor results with only anecdotal long-term survivors.¹⁴ Furthermore, chemosensitivity in STS may vary substantially according to histotype and administered drug. On this basis, cytotoxics for the second- and further-line setting are now increasingly chosen following a histology-driven approach.¹⁵ Indeed, the latest randomized phase 3 trials that led to drug approval (pazopanib,¹⁶ trabectedin,^{17,18} and eribulin^{19,20}) have emphasized this strategy. Unfortunately, the histotype-tailored approach failed to overcome the results of anthracyclines-based regimens in the neoadjuvant setting.^{21,22}

In this context, it has been retrospectively observed that ifosfamide has limited activity in leiomyosarcomas,²³ whereas dacarbazine demonstrated favorable results both as single agent and in combination with gemcitabine.^{18,20,24,25} More than 30 years ago, doxorubicin was compared to doxorubicin+dacarbazine in patients affected by advanced uterine sarcomas and carcinosarcomas. No significant survival advantage or response rate improvement was demonstrated with the combination over doxorubicin considering all histotypes together. Nevertheless, in uterine

leiomyosarcoma the combination achieved a response rate of 30% (6 out of 20 evaluable patients).²⁶ Hence, dacarbazine is increasingly used in combination with doxorubicin as first-line treatment for advanced leiomyosarcoma,^{11,12,27-31} despite we lack a formal prospective evidence to support this choice.

In this scenario of relative uncertainty and in the lack of ongoing controlled prospective studies, we have gathered a large retrospective series of patients affected by advanced/metastatic leiomyosarcoma treated with first-line anthracycline-based regimens within EORTC Soft Tissue and Bone Sarcoma Group (STBSG) referral centers to compare doxorubicin+dacarbazine with doxorubicin either alone or in combination with ifosfamide.

PATIENTS AND METHODS

Patients Selection

This was a multicenter, retrospective study involving reference Institutions within the EORTC STBSG (Table S1). After approval from the Institutional Review Board and/or Ethic Committee of participating Institutions, patients who met the following criteria were included: histologically confirmed and non-surgically resectable or metastatic leiomyosarcoma (including leiomyosarcoma with pleomorphic features);¹ first-line treatment for metastatic disease with doxorubicin either alone or in combination with ifosfamide or dacarbazine started between January 2010 and December 2015; measurable disease (RECIST 1.1); Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2; age ≥ 18 years. Patients with major comorbidities that might jeopardize the interpretation of the data were excluded (*i.e.*, another malignancy within the previous 5 years, or other severe and/or uncontrolled concurrent medical disease).

Outcomes

The primary objective of this study was to explore the activity of doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone as first-line treatments for non-resectable/metastatic leiomyosarcomas. Endpoints of the study included progression-free survival (PFS), overall survival

(OS), and RECIST 1.1 overall response rate (ORR). PFS duration was estimated by an interval-censoring method that accounts for the variable schedules of follow-up measurements in the routine clinical practice.³² Details on endpoints measurement are reported in the appendix (page 2). Data on subsequent treatments were keenly collected.

Due to the absence of randomization we performed matching of patients across treatment arms using a propensity score, *i.e.* an estimate of the probability of each patient to receive one of the three treatments.³³⁻³⁵ We used a 2:1:2 matching ratio resembling the distribution of treatments between the three arms observed in the dataset and then, as a sensitivity analysis, we conducted pairwise 1:1 matching of the three possible treatment pairs. Details on the propensity score methods are available in the appendix (page 2, 7-19; Figure S1-S3; Table S5-S11).

Statistical Analysis

Statistical analyses were performed using SAS statistical software v9.4. A p -value ≤ 0.05 was considered statistically significant. We provide descriptive statistics for population characteristics. Qualitative variables were compared using the χ^2 and Fisher's exact tests. Tests were two-sided and results were reported with 95% confidence intervals (95%CI) or interquartile ranges (IQR) whenever indicated. ORRs were compared among treatment arms by means of the odds ratio (OR) estimates obtained from logistic regression. In order to determine potential predictive factors (histology, site of primary, age, gender, ECOG performance status, tumor extent, and FNCLCC grade) and their related effects, a full multivariate analysis with the administered chemotherapy as additional covariate was run using the interval-censored and the Cox model with Firth adjustment for PFS and OS, respectively. Wald p -values were computed to evaluate the interaction between administered chemotherapy and each factor.

RESULTS

303 patients treated at 18 different EORTC STBSG Institutions from nine European countries were deemed eligible and were included in the present analysis (Figure 1). Marked differences in the

distribution of chemotherapy across the 18 contributing institutions were observed (Table S1). The first-line treatment was doxorubicin plus dacarbazine for 117 (38.6%), doxorubicin plus ifosfamide for 71 (23.4%), and doxorubicin alone for 115 (38.0%) patients. Baseline characteristics of the studied population are reported in Table 1. As expected, fewer patients younger than 50-year-old and more patients over 70-year-old were treated with doxorubicin alone compared to combination regimens. Other characteristics were similar across the three arms with the exception of an excess of inoperable, locally advanced disease without metastases for doxorubicin+ifosfamide arm. At the time of data cutoff (December 22, 2017), only one patient in the doxorubicin+dacarbazine arm was still on treatment. Median number of administered cycles were six, three, and five for doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, respectively. Table 2 reports further details on chemotherapy regimens.

At the time of analysis, the overall median follow-up was 41 months for the whole series (IQR: 26.3-56.7), with shorter follow-up for doxorubicin+dacarbazine [31.7 months (IQR: 23.1-47.2)] compared to both doxorubicin+ifosfamide and doxorubicin alone [50 months (IQR: 37.3-72.7), and 46.1 months (IQR: 31.3-58.4), respectively]. Indeed, patients receiving doxorubicin+dacarbazine were treated more recently and more patients who received this regimen were lost to follow-up or censored for OS. Notably, subsequent treatments were well balanced across the three arms (Table S2).

Unmatched population

Overall, in the 303 patients included in the database, unadjusted median PFS was 9.4 (95%CI 6.1-9.7), 6.8 (4.5-9.5), 5.4 (3.8-6.8) months (Figure 2A, $p=0.0723$, $df=2$) with a 6-month PFS rate of 57.9% (48.0-66.5%), 43.9% (23.9-57.3%), 45% (35.3-54.2%), and an observed ORR of 36.8%, 21.5%, and 25.9%, for doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, respectively. Median OS was 35.4 (28.7-45.7), 21.4 (16.7-26.7), and 29.3 (21.4-33.4) months (Figure 3A, $p=0.0258$), with a 24-month OS rate of 68.8% (58.9-76.8%), 41.9% (30.0-53.3%) and

56.0% (46.1-64.8%) for doxorubicin+dacarbazine, doxorubicin+ifosfamide and doxorubicin alone, respectively.

Adjusting for all baseline factors (histology, site of primary, age, gender, ECOG performance status, tumor extent, and FNCLCC grade) revealed a significant difference in terms of PFS for doxorubicin+dacarbazine vs. doxorubicin (HR 0.60, 95%CI:0.44-0.82, p=0.0014) but not for doxorubicin+ifosfamide vs. doxorubicin HR 0.79 (95%CI: 0.56-1.10). There was no significant difference between groups in terms of OS (HR for doxorubicin + dacarbazine and for doxorubicin + ifosfamide vs. doxorubicin were 0.78 (95%CI: 0.52-1.16) and 1.21 (95%CI: 0.82-1.79), respectively).

Predictive factors

None of the factors included in the multivariate analysis (age, sex, ECOG PS, histotype, site of primary tumor, tumor grade, and tumor extent) appeared predictive for treatment effect in terms of both PFS and OS based on interaction tests (appendix pages 5-6, Table S3-S4). We observed a trend toward a worse outcome for uterine vs. non-uterine origin especially for patients who received doxorubicin alone. Nonetheless, this difference did not reach significance in the overall population and the number of patients affected by uterine leiomyosarcoma did not allow to further explore differences based on site of origin of the primary tumor.

Matched population

After propensity score matching of 205 patients with a 2:1:2 ratio, demographic and baseline tumor characteristics were well balanced with no significant differences between the three arms with the exception of tumor extent that retained an excess of patients with locally advanced disease without metastases in the doxorubicin+ifosfamide arm (Table 1, Figure S1-S3).

In the 2:1:2 matched population, doxorubicin+dacarbazine showed a significantly longer PFS compared to doxorubicin alone [median 9.2 months (95%CI 5.2-9.7) vs. 4.8 (2.3-6.0); HR 0.72 (0.52-0.99)], but not to doxorubicin+ifosfamide [8.2 months (5.2-10.1), HR 1.01 (0.68-1.50)]. PFS did not differ significantly between doxorubicin+ifosfamide and doxorubicin alone [HR 0.71 (0.48-

1.06)]. Estimated 6-month PFS rates were 58.2% (46.4-68.3%), 47.1% (31.5-61.2%), and 42.4% (31.0-53.1%) for doxorubicin+dacarbazine, doxorubicin+ifosfamide, and doxorubicin alone, respectively (Figure 2B).

In the same 2:1:2 matched population, ORR was 30.9% with doxorubicin+dacarbazine, 19.5% with doxorubicin+ifosfamide, and 25.6% with doxorubicin alone [OR 1.70 (0.68-4.24) for doxorubicin+dacarbazine vs. doxorubicin+ifosfamide; OR 1.26 (0.63-2.50) for doxorubicin+dacarbazine vs. doxorubicin alone; and OR 0.74 (0.29-1.86) for doxorubicin+ifosfamide vs. doxorubicin alone].

The estimated median OS was longer with doxorubicin+dacarbazine [36.8 months (95%CI 27.9-47.2)] compared to both doxorubicin+ifosfamide [21.9 months (95%CI 16.7-33.4), HR 0.65 (95%CI 0.40-1.06)] and doxorubicin alone [30.3 months (95%CI 21.0-36.3), HR 0.66 (95%CI 0.43-0.99)] (Figure 3B). OS rates at 12- and 24-month were 81.5% (70.8-88.6%) and 69.6% (57.8-78.7%) with doxorubicin+dacarbazine, 82.9% (67.5-91.5%) and 49.5% (33.1-63.9%) with doxorubicin+ifosfamide, 76.3% (65.4-84.2) and 59.0% (47.2-69.1%) with doxorubicin alone. Indeed, survival curves started to separate after 18 months (Figure 3B).

Adjusted analysis in the matched population

Since there remained minor imbalances in baseline characteristics after matching (Table 1), we also performed comparisons adjusted for baseline factors. The difference between treatments in terms of PFS was statistically significant ($p=0.0023$ overall) with HR 0.53 (95%CI 0.36-0.77, $p=0.0009$) for doxorubicin+dacarbazine vs. doxorubicin and HR 0.58 (95%CI 0.38-0.89, $p=0.0135$) for doxorubicin+ifosfamide vs. doxorubicin. There was no significant difference between groups in terms of OS ($p=0.2089$) with HR 0.70 (95%CI 0.44-1.13, $p=0.1433$) for doxorubicin+dacarbazine vs. doxorubicin and HR 1.07 (95%CI: 0.67-1.71, $p=0.7789$) for doxorubicin+ifosfamide vs. doxorubicin.

Sensitivity analyses

Population characteristics of the new dataset of patients (Figure S1-S3, Table S5-S11) as well as results of the three pairwise matched populations obtained with a 1:1 ratio are reported in the supplementary appendix (Figure S4-S6; Table S12-S14; Figure S7-S9).

DISCUSSION

To our knowledge, this is the largest retrospective study investigating the value of first line treatment for advanced leiomyosarcoma. Despite the limitations of a retrospective study, we observed intriguing signs of activity for doxorubicin and dacarbazine combination both in the unadjusted and in the propensity-score-matched population. In particular, median PFS and ORR were above 9 months and 30%, respectively. These results favorably compare with both historical controls and the results observed with either doxorubicin+ifosfamide or doxorubicin alone in our study.^{13,36-38}

Notably, outcomes of the doxorubicin+dacarbazine arm were also consistent with the few data previously reported for this combination in leiomyosarcomas.^{26,29} Furthermore, although retrospective, the outcomes observed in the doxorubicin alone and in the doxorubicin+ifosfamide arms are consistent with the ones reported in the randomized EORTC 62012 study using the same regimens [median PFS for leiomyosarcoma patients: 6.1 and 6.6 months, respectively (unpublished data)].¹³

Looking at our data from another perspective, this study confirms the limited role of ifosfamide in leiomyosarcoma.^{23,39} Indeed, patients who received this drug reported the lowest response rate and lowest median OS among the three arms, with only a non-significant trend toward an improved PFS compared to doxorubicin alone. Given the retrospective nature of the study, we cannot draw definitive conclusions. Nonetheless, taking also into consideration the relevant toxicities associated with ifosfamide, the use of this drug in leiomyosarcomas should be considered with caution.

Notably, we observed a marked difference in treatment choice across reference Centers in Europe that reflects the current uncertainty on the topic that prompted our study. In particular, some Centers used mainly doxorubicin in combination with either dacarbazine or ifosfamide, whereas others preferentially delivered doxorubicin as monotherapy. The median delivered doses of chemotherapy

are consistent with guidelines and literature data.^{12,39} As frequently observed in clinical practice, doxorubicin in combination with either ifosfamide or dacarbazine was seldom used at a slightly lower dose than the one used when the drug is delivered as monotherapy (nearly 60 vs. 75 mg/m², respectively). Nonetheless, this difference was not statistically significant.

Putting our data in the clinical context of advanced leiomyosarcoma, doxorubicin alone or gemcitabine+docetaxel (+/- bevacizumab) demonstrated a median PFS of about 6 months with a response rate ranging from 10 to 30% at most.^{13,37,38} We decided not to include in our analysis the combination of gemcitabine+docetaxel or the MAID protocol (MESNA, doxorubicin, ifosfamide, and dacarbazine)³⁰ since very few patients have been treated in the first-line setting with these regimens across the 18 reference Centers that contributed in this study. A notable exception in the field of first-line treatments for leiomyosarcoma is represented by the combination of doxorubicin and trabectedin that, up to now, obtained the most promising results. Indeed, in a phase 2, open-label, single-arm study, patients stratified according to uterine and non-uterine origin reported a median PFS of 8 and 13 months with an ORR of about 60% and 40%, respectively.⁵ A phase 3 randomized study comparing this combination with doxorubicin alone in advanced leiomyosarcomas is currently ongoing (NCT02997358), whereas a phase 2 randomized trial that included all STS histotypes did not demonstrate benefit from the addition of trabectedin to doxorubicin.⁴⁰ More recently, preliminary data from the ANNOUNCE trial did not confirm the survival advantage of adding olaratumab to doxorubicin in all STS as well as in leiomyosarcoma.^{36,41}

In our study, the observed OS seems particularly promising and is consistent with the expected longer survival in leiomyosarcoma patients compared to the general sarcoma population.^{2,42}

In our multi-institutional series, the doxorubicin+dacarbazine arm showed the longest survival both in the unadjusted and in the propensity-score-matched population, but the shorter follow-up of this arm weakens the comparison among the three regimens. Although a median follow-up of 32 months could be considered adequate in the STS setting being more than two times longer than the expected median survival for this population,^{13,36} the observed excess of censored patients in this arm might

indeed lead to an overestimation of OS by means of Kaplan-Meier method. Despite this potential issue in OS evaluation, the follow-up length does not affect PFS estimation.

The limitations of the present study are mainly related to its retrospective nature. As mentioned above, there is a potential bias in center-specific chemotherapy preference. Moreover, as in the great majority of retrospective studies, we did not perform a central pathological review of the diagnosis or a central review of radiological responses. Nonetheless, both these potential issues are limited by the fact that data came from reference centers across Europe. Indeed, the great majority of the diagnoses have been confirmed by reference sarcoma pathologists in each country, and disease responses have been reviewed by the involved investigator(s) at each site according to RECIST 1.1. Another potential bias is related to the risk of PFS overestimation due to longer time intervals between CT scans that could delay disease progression detection. Nonetheless, the risk of this bias was greatly limited by our choice of an interval-censoring approach to the data analysis. This choice allowed for a better PFS estimation that, as mentioned above, was superimposable to the outcomes observed in the prospective EORTC 62012 trial for both doxorubicin alone and doxorubicin+ifosfamide arm.¹³

In the lack of prospective randomized studies and in light of the negative results of the ANNOUNCE trial, data from analyses based on adjustment for baseline covariates and propensity score matching represent a relevant source of information although they should remain mainly hypothesis-generating. Propensity score allowed us to reduce the bias related to treatment allocation in a non-randomized, retrospective study and was based on the most relevant covariates available in our database. However, matching has the limitation to diminish the total number of matched patients to the arm with the lowest recruitment (in our study doxorubicin+ifosfamide), thus reducing the power of the analysis and limiting the generalization of the estimated effect.³³⁻³⁵ That said, the results of adjusted analyses in the matched and unmatched populations appear consistent and suggest that PFS might be superior in the group of patients treated with doxorubicin+dacarbazine compared to doxorubicin alone.

In conclusion, our study showed that doxorubicin and dacarbazine combination is an intriguing treatment option for leiomyosarcoma that deserves further investigations in prospective trials. Indeed, based on these results, a phase 3 randomized study is currently being developed within the frame of the EORTC Soft Tissue and Bone Sarcoma Group aiming to explore the role of neoadjuvant doxorubicin+dacarbazine compared to surgery alone in patients affected by high grade, >5 cm, localized retroperitoneal leiomyosarcoma (STRASS2 study).

REFERENCES

1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. *WHO Classification of Tumours of Soft Tissue and Bone*. 4th ed. Lyon 2013.
2. George S, Serrano C, Hensley ML, Ray-Coquard I. Soft Tissue and Uterine Leiomyosarcoma. *J Clin Oncol*. 2018;36(2):144-150.
3. Beck AH, Lee CH, Witten DM, et al. Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. *Oncogene*. 2010;29(6):845-854.
4. Guo X, Jo VY, Mills AM, et al. Clinically Relevant Molecular Subtypes in Leiomyosarcoma. *Clin Cancer Res*. 2015;21(15):3501-3511.
5. Pautier P, Floquet A, Chevreau C, et al. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial. *Lancet Oncol*. 2015;16(4):457-464.
6. Network CGAR. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*. 2017;171(4):950-965.e928.
7. Lucchesi C, Khalifa E, Laizet Y, et al. Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy. *JAMA Oncol*. 2018;4(10):1398-1404.
8. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. *Ann Surg*. 2014;260(3):416-421; discussion 421-412.
9. Gronchi A, Lo Vullo S, Colombo C, et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. *Ann Surg*. 2010;251(3):506-511.
10. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. *Int J Radiat Oncol Biol Phys*. 2003;57(3):739-747.

11. von Mehren M, Randall RL, Benjamin RS, et al. Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2018;16(5):536-563.
12. Casali PG, Abecassis N, Bauer S, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018.
13. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *Lancet Oncol*. 2014;15(4):415-423.
14. Blay JY, van Glabbeke M, Verweij J, et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. *Eur J Cancer*. 2003;39(1):64-69.
15. Casali PG. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. *Ann Oncol*. 2012;23 Suppl 10:x167-169.
16. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*. 2012;379(9829):1879-1886.
17. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. *J Clin Oncol*. 2009;27(25):4188-4196.
18. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. *J Clin Oncol*. 2015.
19. Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. *Lancet Oncol*. 2011;12(11):1045-1052.

20. Schöffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. *Lancet*. 2016.
21. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STSS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. *Lancet Oncol*. 2017;18(6):812-822.
22. Zaidi MY, Ethun CG, Tran TB, et al. Assessing the Role of Neoadjuvant Chemotherapy in Primary High-Risk Truncal/Extremity Soft Tissue Sarcomas: An Analysis of the Multi-institutional U.S. Sarcoma Collaborative. *Ann Surg Oncol*. 2019;26(11):3542-3549.
23. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). *Eur J Cancer*. 2010;46(1):72-83.
24. Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. *Cancer Treat Rep*. 1976;60(2):199-203.
25. García-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. *J Clin Oncol*. 2011;29(18):2528-2533.
26. Omura GA, Major FJ, Blessing JA, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer*. 1983;52(4):626-632.
27. Saiki JH, Baker LH, Rivkin SE, et al. A useful high-dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas. *Cancer*. 1986;58(10):2196-2197.

28. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. *J Natl Cancer Inst.* 1991;83(13):926-932.
29. Bitz U, Pink D, Busemann C, Reichardt P. Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). Paper presented at: 2011 ASCO Annual Meeting 2011.
30. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol.* 1993;11(7):1276-1285.
31. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. *J Clin Oncol.* 1987;5(6):840-850.
32. Finkelstein DM, Wolfe RA. A semiparametric model for regression analysis of interval-censored failure time data. *Biometrics.* 1985;41(4):933-945.
33. Lechner M, ed *Identification and estimation of causal effects of multiple treatments under the conditional independence assumption.* Heidelberg: Physica 2001. Econometric Evaluation of Labour Market Policies. ZEW Economic Studies (Publication Series of the Centre for European Economic Research (ZEW), Mannheim, Germany).
34. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. *Am J Epidemiol.* 2011;173(12):1404-1413.
35. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. *Pharmacoepidemiol Drug Saf.* 2012;21(7):697-709.
36. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. *Lancet.* 2016;388(10043):488-497.

37. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. *Lancet Oncol.* 2017;18(10):1397-1410.
38. Hensley ML, Miller A, O'Malley DM, et al. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. *J Clin Oncol.* 2015;33(10):1180-1185.
39. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. *J Clin Oncol.* 2000;18(14):2676-2684.
40. Martin-Broto J, Pousa AL, de Las Peñas R, et al. Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study. *J Clin Oncol.* 2016;34(19):2294-2302.
41. Tap W, Wagner A, Papai Z, et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). *J Clin Oncol.* 2019(suppl; abstr LBA3).
42. Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. *Clin Sarcoma Res.* 2018;8:8.

FIGURES LEGENDS

Figure 1. CONSORT diagram.

Figure 2. Progression-free survival. Panel A, unadjusted population; Panel B, 2:1:2 propensity-score-matched population for the three treatment arms. Purple line doxorubicin plus dacarbazine, blue line doxorubicin plus ifosfamide, red line doxorubicin alone.

Figure 3. Overall survival. Panel A, unadjusted population; Panel B, 2:1:2 propensity-score-matched population for the three treatment arms. Purple line doxorubicin plus dacarbazine, blue line doxorubicin plus ifosfamide, red line doxorubicin alone.